Novasenta Completes $40 million Series A to Advance Novel Cancer Therapeutics
PITTSBURGH, July 29, 2022 -- (Healthcare Sales & Marketing Network) -- Novasenta Inc., a startup biotechnology company focused on the discovery and validation of novel targets to develop cancer therapies, today announced the completion of $40 million in S... Biopharmaceuticals, Oncology, Venture Capital Novasenta, tumor microenvironment
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Cancer Therapy | Marketing | Pharmaceuticals | Venture Capital